-- 1 of 24 -- 2 nd Quarter 2026 Earnings Call July 15, 2026 -- 2 of 24 -- Cautionary note on Forward-looking statements This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; and the Company's ability to successfully separate the Company's Orthopaedics business and realize the anticipated benefits from the planned separation. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, investor.jnj.com, or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Cautionary note on Non-GAAP financial measures This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the Company’s website. 3 -- 3 of 24 -- Oncology IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company; ZYTIGA licensed from BTG International Ltd.; VELCADE developed in collaboration with Millennium: The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO licensed from Genmab A/S; BALVERSA licensed and discovered in collaboration with Astex Pharmaceuticals, Inc.; ERLEADA licensed from Regents of California and Memorial Sloan Kettering; CARVYKTI licensed and developed in collaboration with Legend Biotech USA Inc. and Legend Biotech Ireland Limited; AKEEGA licensed from TESARO, Inc., an oncology-focused business within GSK, and from BTG International Ltd.; RYBREVANT developed under license with Genmab A/S; LAZCLUZE licensed from Yuhan Corporation; DuoBody platform licensed from Genmab A/S relates to several bispecific antibody programs; OMT animal platform licensed from OMT Inc. relates to several antibody programs; ENHANZE platform licensed from Halozyme Therapeutics, Inc.; bleximenib R&D co-funding agreement with Blackstone Life Sciences Immunology REMICADE and SIMPONI/ SIMPONI ARIA marketing partner with Mitsubishi Tanabe Pharma Corporation; TREMFYA discovered using MorphoSys AG antibody technology; ICOTYDE was discovered through a collaboration with Protagonist Therapeutics – Janssen retains exclusive rights to develop and commercialize for a broad range of indications; JNJ-4804 R&D co-funding agreement with Royalty Pharma plc Neuroscience INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA/ INVEGA HAFYERA/ BYANNLI are subject to a technology license agreement from Alkermes Pharma Ireland Limited, and RISPERDAL CONSTA developed in collaboration with Alkermes, Inc. Other PREZCOBIX / REZOLSTA fixed-dose combination, SYMTUZA and ODEFSEY developed in collaboration with Gilead Sciences, Inc., and JULUCA and CABENUVA developed in collaboration with ViiV Healthcare UK., INVOKANA/ INVOKAMET/ VOKANAMET/ INVOKAMET XR fixed-dose combination licensed from Mitsubishi Tanabe Pharma Corporation; XARELTO co-developed with Bayer HealthCare AG; PROCRIT/ EPREX licensed from Amgen Inc.; UPTRAVI license and supply agreement with Nippon Shinyaku (co-promotion in Japan), and OPSUMIT co-promotion agreement with Nippon Shinyaku in Japan Strategic partnerships, collaborations & licensing arrangements During the course of this presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or licensed from other companies. The following is an acknowledgement of those relationships: 4 -- 4 of 24 -- CEO Remarks Sales performance and earnings review Capital allocation and guidance update Q&A Agenda 5 John Reed Executive Vice President, Innovative Medicine, R&D Joaquin Duato Chairman and Chief Executive Officer Joseph J. Wolk Executive Vice President, Chief Financial Officer Ryan Koors Vice President, Investor Relations Jennifer Taubert Executive Vice President, Worldwide Chairman, Innovative Medicine Tim Schmid Executive Vice President, Worldwide Chairman, MedTech 1 2 3 4 -- 5 of 24 -- Joaquin Duato Chairman and Chief Executive Officer -- 6 of 24 -- 7 Q2 Earnings Summary 5.6% operational sales growth 1,2 Six key businesses driving growth 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 2 Includes an approximate (460) basis point headwind from STELARA -- 7 of 24 -- Innovative Medicine: 6.8% operational sales growth 1,2 8 Oncology Neuroscience Immunology 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 2 Includes an approximate (760) basis point headwind from STELARA Note: Includes existing products and planned future launches -- 8 of 24 -- MedTech: 3.6% operational sales growth1 9 Cardiovascular Surgery Vision VARIPULSE Platform Dual Energy THERMOCOOL SMARTTOUCH SF Catheter Shockwave Intravascular Lithotripsy System OMNYPULSE Catheter Impella® Heart Pump Technology OTTAVA Robotic Surgical System ETHICON 4000 Surgical Stapler ACUVUE® OASYS 1-Day Family TECNIS Odyssey TECNIS PureSee MONARCH Flexible Robotics Platform 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website Note: Includes existing products and planned future launches -- 9 of 24 -- Leading the next wave of healthcare innovation 10 -- 10 of 24 -- Ryan Koors Vice President, Investor Relations -- 11 of 24 -- Regional sales results Q2 2026 Q2 2025 % Change Reported Operational 1 U.S. $14.5 $13.5 7.3% 7.3% Europe 5.7 5.4 6.3 3.3 Western Hemisphere (ex U.S.) 1.3 1.2 8.5 2.7 Asia-Pacific, Africa 3.7 3.6 3.8 3.9 International 10.8 10.2 5.7 3.4 Worldwide (WW) $25.3 $23.7 6.6% 5.6% Dollars in billions 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website Note: Values may be rounded 2nd Quarter 2026 sales 12 -- 12 of 24 -- $25.3 $23.7 $7.1 $6.7 4.7%; 3.2% 1 $2.90 $2.77 Dollars in billions, except EPS Reported %; Operational %1 Sales Adjusted earnings2 Adjusted EPS 2 6.6%; 5.6% 1 GAAP earnings 5.7% Q2 2026 Q2 2025 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website 2nd Quarter 2026 financial highlights GAAP EPS 13 Q2 2026 Q2 2025 Q2 2026 Q2 2025 Q2 2026 Q2 2025 Q2 2026 Q2 2025 (0.1)% (0.9)% $5.5 $5.5 $2.27 $2.29 -- 13 of 24 -- Other $2,795 Neuroscience $2,337 Oncology $7,406 Immunology $3,844 ■ Reported growth ■ Operational growth1 $16,384 7.8%, 6.8% WW sales $MM Key drivers of operational performance 1 Oncology • DARZALEX increase primarily driven by strong share gains and market growth • CARVYKTI increase driven by share gains and continued site expansion • TECVAYLI growth driven by launch uptake, share gains following U.S. TECVAYLI + DARZALEX FASPRO approval, and from expansion in the community setting • TALVEY growth driven by share gains from expansion in the community setting • RYBREVANT/LAZCLUZE growth driven by launch uptake and share gains • ERLEADA increase driven by continued share gains in mCSPC and market growth, partially offset by unfavorable patient mix and inventory dynamics • IMBRUVICA decrease driven by share loss due to continued competitive pressure and unfavorable patient mix Immunology • TREMFYA growth due to share gains across all indications with significant IBD launch momentum and market growth • SIMPONI/SIMPONI ARIA and REMICADE decrease driven by share loss, biosimilar competition, and unfavorable patient mix, partially offset by market growth • STELARA decline driven by the impact of biosimilar competition, increasing adoption of novel classes, and unfavorable patient mix • OTHER IMMUNOLOGY increase driven by IMAAVY and ICOTYDE in the U.S. Neuroscience • SPRAVATO growth driven by continued increased physician and patient demand • CAPLYTA growth driven by strong continued momentum in the aMDD launch • INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA increase primarily driven by favorable patient mix, partially offset by share loss and inventory dynamics Other • UPTRAVI increase driven by market and share growth, partially offset by unfavorable patient mix • OPSUMIT/OPSYNVI growth driven by share gains and market growth, partially offset by U.S. LOE-related inventory burn • PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA decrease driven by declines in share and market, partially offset by favorable patient mix • XARELTO increase driven by favorable patient mix, partially offset by continued share erosion Adjusted operational sales 2 : WW 6.9%, U.S. 8.9%, Int’l 3.8% Innovative Medicine highlights – 2nd quarter 2026 Reported: WW 7.8%, U.S. 8.9%, Int’l 6.0% Operational 1: WW 6.8%, U.S. 8.9%, Int’l 3.6% (3.7)%, (4.6)% 17.3%, 16.1% (1.8)%, (2.4)% Strong operational growth 1 of 6.8% driven primarily by new product launches 14.0%, 13.4% 14 Stelara impacted results 1 by ~(760) basis points 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the company's website Note: Values may be rounded -- 14 of 24 -- Key drivers of operational performance 1 Cardiovascular • Electrophysiology: Increase driven by procedure growth, commercial execution, new product performance (VARIPULSE, TRUPULSE, NUVISION and CRYSTAL), partially offset by competitive pressures in PFA and China inventory dynamics • Abiomed: Decline driven by lower U.S. procedure volumes, partially offset by continued OUS growth including sustained adoption of Impella 5.5 • Shockwave: Double-digit growth driven by continued strong adoption of Coronary and Peripheral portfolios and new product launches (AERO C2) Surgery • Advanced: • Biosurgery: ~ +9% growth driven by continued strength of the portfolio and commercial execution, partially offset by the impact of the surgery transformation program and VBP in China • Endocutters: ~ -5% due to competitive pressures and VBP in China • Energy: ~ -1% driven by impact of the surgery transformation program, VBP in China, and competitive pressures, partially offset by new product launches • General: Increase primarily due to technology penetration and upgrades within our differentiated Wound Closure portfolio (Barbed & PLUS Sutures) and market expansion, partially offset by VBP in China Vision • Contact Lenses/Other: Increase driven by strong performance of the ACUVUE OASYS 1-Day family of products including recent launches and strategic price actions, partially offset by inventory dynamics • Surgical: Growth driven by strength of recent product innovations, robust demand for premium IOLs, and strong commercial execution, partially offset by competitive pressures in the U.S. Orthopaedics Growth across all platforms primarily driven by new product launches and strong commercial execution: • Hips: Increase driven by new product launches (EMPHASYS) • Knees: Increase driven by strength of the ATTUNE portfolio, in part driven by pull through related to the VELYS Robotic assisted solutions • Trauma: Growth driven by recently launched products (VOLT) • Spine, Sports & Other: Increase driven by new product innovations as well as growth in shoulders, partially offset by competitive pressures and inventory dynamics Adjusted operational sales 2 : WW 3.7%, U.S. 4.1%, Int’l 3.2% Surgery $2,653 Orthopaedics $2,418 Vision $1,451 Cardiovascular $2,404 ■ Reported growth ■ Operational growth 1 $8,926 4.5%, 3.6% WW sales $MM Solid operational growth1 of 3.6% driven primarily by commercial execution and innovation Reported: WW 4.5%, U.S. 3.9%, Int’l 5.2% Operational 1: WW 3.6%, U.S. 3.9%, Int’l 3.2% 4.0%, 3.1% 6.0%, 5.6% 3.9%, 2.3% 4.9%, 4.2% MedTech highlights – 2nd quarter 2026 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the company's website Note: Values may be rounded 15 -- 15 of 24 -- 2026 2025 % Increase (Decrease) Amount % to Sales Amount % to Sales Sales to customers $25,310 100.0 $23,743 100.0 6.6 Cost of products sold 8,051 31.8 7,628 32.1 5.5 Gross Profit 17,259 68.2 16,115 67.9 7.1 Selling, marketing and administrative expenses 6,432 25.4 5,889 24.8 9.2 Research and development expense 3,653 14.4 3,516 14.8 3.9 Interest (income) expense, net 62 0.2 48 0.2 Other (income) expense, net 331 1.3 107 0.5 Restructuring 34 0.2 64 0.3 Earnings before provision for taxes on income 6,747 26.7 6,491 27.3 3.9 Provision for taxes on income 1,213 4.8 954 4.0 27.1 Net Earnings $5,534 21.9 $5,537 23.3 (0.1) Net earnings per share (Diluted) $2.27 $2.29 (0.9) Average shares outstanding (Diluted) 2,440.1 2,419.1 Effective tax rate 18.0% 14.7% Adjusted earnings before provision for taxes and net earnings1 Earnings before provision for taxes on income $8,660 34.2 $8,188 34.5 5.8 Net earnings $7,081 28.0 $6,699 28.2 5.7 Net earnings per share (Diluted) $2.90 $2.77 4.7 Effective tax rate 18.2% 18.2% 1 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website (Unaudited; Dollars and shares in millions except per share figures) 16 2 nd Quarter 2026 Condensed consolidated statement of earnings -- 16 of 24 -- Innovative Medicine 2026 2025 % Increase (Decrease) Amount % to Sales Amount % to Sales Sales to customers $16,384 100.0 $15,202 100.0 7.8 Cost of products sold 3,505 21.4 3,180 20.9 10.2 Gross Profit $12,879 78.6 $12,022 79.1 7.1 Selling, marketing and administrative expenses 3,130 19.1 2,789 18.3 12.2 Research and development expense 2,875 17.5 2,869 18.9 0.2 Other segment items 1 (84) (0.5) (129) (0.8) Adjusted segment income before tax 2 $6,958 42.5 $6,493 42.7 7.2 (Unaudited; Dollars in millions) Adjusted earnings before provision for taxes on income by segment 17 MedTech 2026 2025 % Increase (Decrease) Amount % to Sales Amount % to Sales Sales to customers $8,926 100.0 $8,541 100.0 4.5 Cost of products sold 3,236 36.3 3,142 36.8 3.0 Gross Profit $5,690 63.7 $5,399 63.2 5.4 Selling, marketing and administrative expenses 3,052 34.2 2,862 33.4 6.6 Research and development expense 776 8.7 690 8.1 12.5 Other segment items 1 (105) (1.2) (53) (0.6) Adjusted segment income before tax 2 $1,967 22.0 $1,900 22.2 3.5 Enterprise 2026 2025 % Increase (Decrease) Amount % to Sales Amount % to Sales Adjusted income before tax 2 $8,660 34.2 $8,188 34.5 5.8 2 nd Quarter 2026 1 Includes other Income and Expense 2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website Note: For expenses not allocated to segments, see reconciliation schedules on the Investor Relations section of the company's website -- 17 of 24 -- Joseph J. Wolk Executive Vice President, Chief Financial Officer -- 18 of 24 -- Capital allocation Organic growth business needs Free cash flow 1 Priorities are clear and remain unchanged Competitive dividends Share repurchases Higher priority Lower priority Investment in M&A Dollars in billions Q2 2026 Cash and marketable securities $20.8 Debt ($49.0) Net debt ($28.2) Free cash flow1,2 ~$8.7 Q2 2026: $3.7B invested in R&D $7.2B year-to-date $3.3B in dividends paid to shareholders $6.4B year-to-date Note: Values may be rounded 1 Non-GAAP measure; defined as cash flow from operating activities, less additions to property, plant and equipment 2 Estimated as of July 15, 2026. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings Note: Values may be rounded Capital allocation strategy 19 -- 19 of 24 -- Operational2 sales guidance of 6.8% and adjusted operational EPS 2,4 at 7.3% (midpoints) July 2026 April 2026 Comments Adjusted operational sales 1,2 6.2% - 6.8% 5.6% - 6.6% Tightening range; Increasing midpoint to 6.5% Operational sales 2 $100.3B - $100.9B 6.5% - 7.1% $99.7B - $100.7B 5.9% - 6.9% Tightening range; Increasing midpoint by $0.4B to 6.8% Estimated reported sales 3 $100.8B - $101.4B 7.0% - 7.6% $100.3B - $101.3B 6.5% - 7.5% Tightening range; Increasing midpoint by $0.3B to 7.3% FX impact of ($0.1B) or (0.1)% Adjusted pre-tax operating margin4,5 Increase of approximately 75 bps Increase of at least 50 bps Increasing Net other income 4 $1.0 - $1.2 billion $1.0 - $1.2 billion Maintaining Net interest expense / (income) $250 - $350 million $300 - $400 million Decreasing Effective tax rate 4 17.0% - 18.0% 17.5% - 18.5% Decreasing Adjusted EPS (operational) 2,4 $11.50 - $11.65 6.6% - 8.0% $11.30 - $11.50 4.7% - 6.7% Tightening range; Increasing midpoint by $0.18 to 7.3% Adjusted EPS (reported) 3,4 $11.60 - $11.75 7.5% - 8.9% $11.45 - $11.65 6.1% - 8.1% Tightening range; Increasing midpoint by $0.13 to 8.2% FX impact of ($0.05) or (0.5)% 2026 P&L guidance 1 Non-GAAP measure; excludes acquisitions and divestitures 4 Non-GAAP measure; excludes intangible amortization expense and special items 2 Non-GAAP measure; excludes the impact of translational currency 5 Sales less: COGS, SM&A and R&D expenses 3 Calculated using Euro Average Rate: July 2026 = $1.15 and April 2026 = $1.17 Note: Values may be rounded 20 -- 20 of 24 -- Innovative Medicine Anticipated 2026 milestones1 driving long-term value creation MedTech 21 TECVAYLI + TALVEY in RRMM Pasritamig in prostate cancer JNJ-6143 in prostate cancer INLEXZO in HR NMIBC ICOTYDE in PsA CAPLYTA in bipolar mania TREMFYA in PsA SD nipocalimab in WAIHA and SLE Dual Energy THERMOCOOL STSF C2 Aero Catheters VARIPULSE Pro OTTAVA ETHICON 4000 TECNIS PureSee IOL MONARCH Urology VOLT suite of products 1 List above is not inclusive of all 2026 anticipated milestones across approvals, planned submissions, potential clinical data presentations, and launches RRMM: Relapsed/refractory multiple myeloma; HR NMIBC: High-risk non-muscle invasive bladder cancer; PsA: Psoriatic arthritis; PsA SD: Psoriatic arthritis structural damage; WAIHA: Warm autoimmune hemolytic anemia; SLE: Systemic lupus erythematosus; STSF: SMARTTOUCH Surround Flow; IOL: Intraocular lens -- 21 of 24 -- Q&A John Reed Executive Vice President, Innovative Medicine, R&D Joaquin Duato Chairman and Chief Executive Officer Joseph J. Wolk Executive Vice President, Chief Financial Officer Ryan Koors Vice President, Investor Relations Jennifer Taubert Executive Vice President, Worldwide Chairman, Innovative Medicine Tim Schmid Executive Vice President, Worldwide Chairman, MedTech -- 22 of 24 -- Slide footer goes here if required 23 -- 23 of 24 -- POTENTIAL APPROVALS US/EU PLANNED SUBMISSIONS US/EU POTENTIAL CLINICAL DATA PRESENTATIONS¹ Phase III Phase I/ II  US TREMFYA (guselkumab)  US nipocalimab US ERLEADA (apalutamide)  ICOTYDE (icotrokinra) ERLEADA (apalutamide)  JNJ-4804 Co-antibody Therapy Psoriatic Arthritis Structural Damage (APEX) Warm Autoimmune Hemolytic Anemia (ENERGY) EU Localized Prostate Cancer (ATLAS) Psoriasis (ICONIC-ADVANCE 1&2 Update) Localized Prostate Cancer (ATLAS) Ulcerative Colitis (DUET-UC)  US ICOTYDE (icotrokinra) US CAPLYTA (lumateperone) US ERLEADA (apalutamide) ICOTYDE (icotrokinra)  ERLEADA (apalutamide)  JNJ-4804 Co-antibody Therapy EU Psoriasis (ICONIC) Bipolar Mania EU High Risk Prostate Cancer (PROTEUS) Psoriasis (ICONIC-ASCEND) High Risk Prostate Cancer (PROTEUS) Crohn's Disease (DUET-CD) US nipocalimab US bleximenib icotrokinra  TALVEY (talquetamab)  JNJ-4804 Co-antibody Therapy Warm Autoimmune Hemolytic Anemia (ENERGY) Relapsed Refractory Acute Myeloid Leukemia (cAMeLot-1) Psoriatic Arthritis (ICONIC- PsA) Relapsed Refractory Multiple Myeloma A-CD38 Naïve (MonumenTAL-3) Psoriatic Arthritis (AFFINITY) AKEEGA (niraparib/abiraterone)  US TALVEY (talquetamab) ICOTYDE (icotrokinra) TALVEY (talquetamab)  nipocalimab EU M1 Metastatic Castration- Sensitive Prostate Cancer (AMPLITUDE)  EU Relapsed Refractory Multiple Myeloma A-CD38 Naïve (MonumenTAL-3) Psoriasis (ICONIC-TOTAL Update) Relapsed Refractory Multiple Myeloma CD38 exposed (MonumenTAL-6) Systemic Lupus Erythematosus (JASMINE)  US DARZALEX (daratumumab) US TALVEY (talquetamab) CAPLYTA (lumateperone)  TECVAYLI (teclistamab) bleximenib Frontline multiple myeloma transplant ineligible (CEPHEUS) EU Relapsed Refractory Multiple Myeloma CD38 exposed (MonumenTAL-6) Bipolar Mania (ITI-007-452) Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC-9) Relapsed Refractory Acute Myeloid Leukemia (cAMeLot-1)  US TECVAYLI (teclistamab)  US TECVAYLI (teclistamab)  nipocalimab INLEXZO (gemcitabine intravesical delivery system) pasritamig + JNJ-9401 EU Multiple Myeloma 1-3PLs (MajesTEC-3)  EU Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC-9) Warm Autoimmune Hemolytic Anemia (ENERGY) High Risk Non Muscle Invasive Bladder Cancer BCG Experienced (SunRISe-5) Prostate Cancer (PCR1001) TECVAYLI (teclistamab) TECVAYLI (teclistamab) JNJ-6143 (HLD-0915) EU Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC-9)  EU Multiple Myeloma 1-3PLs (MajesTEC-3) Prostate Cancer (FIH Update)  US RYBREVANT (amivantamab) Head and Neck Cancer (ORIGAMI-4) US INLEXZO (gemcitabine intravesical delivery system) EU High Risk Non Muscle Invasive Bladder Cancer BCG Experienced (SunRISe-5) Johnson & Johnson Innovative Medicine Pipeline Key Events in 2026* 1. In order to be on key events clinical presentation, data must be presented at a major medical meeting. *This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investment. This information is as of July 15, 2026 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. = Achieved -- 24 of 24 --